What the documents list, and what sits nearby
There is no dental entry in any of the three tirzepatide documents [1][3][4]. The effects closest to the mouth come from SURMOUNT-1 and SURMOUNT-2, the 72-week weight trials, and the label says the two sleep apnea trials showed a similar pattern [1].
| Reaction | Zepbound® 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Vomiting, US [1] | 8% | 11% | 13% | 2% |
| Gastroesophageal reflux disease, US [1] | 4% | 4% | 5% | 2% |
| Indigestion (dyspepsia), US [1] | 9% | 9% | 10% | 4% |
| Dry mouth, Canada [3] | 0.8% | 1.2% | 0.7% | 0.1% |
| EU, tirzepatide as Mounjaro® [4] | No tooth or gum entry; reflux classed as common |
Sedation and dental procedures
Zepbound® delays stomach emptying [1]. After approval, rare cases of pulmonary aspiration, food or liquid from the stomach entering the lungs, were reported in people taking GLP-1 medicines who had general anaesthesia or deep sedation for elective procedures, even when they had followed fasting instructions [1]. The European information asks clinicians to consider leftover stomach contents before such procedures [4].
This matters at the dentist when treatment involves deep sedation or general anaesthesia, as some oral surgery does. The US label does not tell you to stop Zepbound® beforehand: it says the data are too limited to recommend changing fasting rules or pausing the medicine, and asks patients to tell their providers before any planned procedure [1]. The Medication Guide puts it as telling all your healthcare providers, which includes the dental team [2]. Any change to the plan is for them to decide together.
Sleep apnea brings you to the dentist too
In the US, Zepbound® is approved to treat moderate or severe obstructive sleep apnea when a person also has obesity [1]; MedlinePlus records that the FDA approval for this use came in December 2024 [13]. The same MedlinePlus page lists dental devices, worn at night to hold the jaw forward and keep the airway open, among sleep apnea treatments [13].
A 2025 review in the Journal of the American Dental Association, written for dental teams, points out that dentists help spot people at risk of sleep apnea, provide oral appliance therapy and work with medical colleagues. It suggests tirzepatide could affect oral care, including periodontal treatment, dental implants and orthodontics, though it does not report measured effects [5]. If you wear a sleep apnea appliance and are losing weight on Zepbound®, tell both your dentist and your sleep team, since the appliance was fitted to your mouth and airway as they were.
Acid and saliva: how teeth could be affected
The possible routes, ranked by how well they are supported:
- Supported by the label. Vomiting and reflux are more frequent on Zepbound® than on placebo, and both bring stomach acid into contact with teeth; most vomiting happened while the dose was being increased [1]. A dry mouth or throat was reported by 1% on Zepbound® against 0.1% on placebo [1].
- Proposed but not proven. A 2026 oral medicine review says that less saliva combined with acid from reflux or vomiting may make teeth more prone to erosion, but notes that a direct link with these medicines has not been established [8].
- General dental knowledge. Saliva washes the teeth and carries calcium and phosphate that keep enamel strong, so a persistently dry mouth raises the risk of decay and mouth infections [10]. Bacteria turning sugars and starches into acid is what starts decay, and repeated exposure keeps enamel losing minerals [11].
What gum studies have found
The largest tirzepatide study on oral outcomes used health records of adults with type 2 diabetes, matching 97,993 people starting tirzepatide with the same number starting a GLP-1 medicine. Over one year, tirzepatide users had lower recorded rates of periodontitis, tooth extraction, complications around implants and oral infections [6]. Event rates were low and the data came from routine records rather than dental examinations, so the authors call for prospective studies [6]. The participants had diabetes, which is not the main group Zepbound® is prescribed for.
A 2026 scoping review in the Journal of Periodontology found laboratory and animal evidence that GLP-1 medicines can influence the inflammation behind gum disease, but described the human evidence as indirect and insufficient to show any benefit for gums [7].
Other reasons teeth and gums suffer
According to NIDCR, plaque left on teeth hardens into tartar and drives gum disease; smoking or tobacco use is the most significant risk factor, and older age, diabetes and genetics also raise risk, with gum disease more common in men [12]. Receding gums expose tooth roots to decay in older adults [11].
Diabetes deserves its own mention, since about a quarter of people in Zepbound®’s weight trials had type 2 diabetes [1]. NIDCR explains that diabetes raises the chance of gum disease, can cause dry mouth and thrush, and slows healing, and that gum disease can in turn make blood sugar harder to control [9]. Hundreds of medicines, including some for blood pressure and depression, can reduce saliva [10].
Protecting your teeth on Zepbound®
NIDCR’s advice is to brush twice a day with fluoride toothpaste, clean between the teeth with floss or another interdental cleaner, limit sugary drinks and foods high in sugar and starch, avoid tobacco and see a dentist for regular check-ups and cleaning [11][12]. If you have moved to many small meals and snacks, its point about frequent sugary or starchy eating is worth keeping in mind [11].
For a dry mouth, NIDCR suggests drinking water often, sipping water with meals, chewing sugarless gum, and cutting back on caffeine, tobacco and alcohol, and it asks you to see a dentist or doctor to find the cause [10]. People with diabetes are asked to tell their dentist about it and to report swollen or bleeding gums, soreness, white patches or a bad taste [9].
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Toothache with facial swelling and fever | Your dentist the same day (possible abscess) | Today | NIDCR [11] |
| Vomiting that keeps returning or will not stop | Your prescriber promptly; acid exposure to teeth is one more reason | Today | Medication Guide [2] |
| A planned dental procedure with deep sedation or general anaesthesia | Tell your dentist and prescriber well before the appointment | At your next appointment | Label §5.9 and §17 [1]; Medication Guide [2] |
| Swollen or bleeding gums, soreness, white patches or a bad taste, especially with diabetes | Your dentist | At your next appointment | NIDCR [9] |
| New sensitivity to sweets, heat or cold, or stained spots on teeth | Your dentist (possible early decay) | At your next appointment | NIDCR [11] |
| A mouth that stays dry | Your dentist or doctor, to find the cause | At your next appointment | NIDCR [10] |